Search for Novartis AG and
    1. 18 hours ago

      Activist investors: hard drugs

      Failed in New Jersey? Try Basel. Investors in Johnson & Johnson have tried to gin up interest among activists in...

    2. February 3, 2016

      GSK’s Witty avoids the City’s would-be surgeons

      Sir Andrew Witty, chief executive of GlaxoSmithKline, is having his yearly City health check up. Corporate doctor: What...

    Special Reports

    1. Corporate Longevity

      The FT launches a global investigation into the mixture of innovation and focus that c...
    2. Doing Business in Wallonia

      Wallonia’s economy is quite diverse. But with a diet of bullets and pills, it is not a...
    Search more Special Reports on this topic.

    1. February 1, 2016

      Investor calls for big pharma to slim down grow louder

      Some of the world’s biggest pharmaceuticals groups are facing calls to break up their diversified businesses in favour...

    2. January 27, 2016

      Novartis revamps Alcon eyecare division

      Novartis has set a deadline for its struggling eyecare business to return to growth by the end of this year or risk...

    3. Fast FT

      January 27, 2016

      Novartis to streamline operations, misses estimates

      Novartis has announced plans to streamline its operations as a strong US dollar continued to weigh on its earnings. The...

    4. January 21, 2016

      Drugmakers call for collective action on superbugs

      Most of the world’s biggest pharmaceuticals groups have backed a declaration committing the industry to help tackle...

    5. January 20, 2016

      GlaxoSmithKline and Qualcomm in talks over health tech tie-up

      GlaxoSmithKline and Qualcomm are in talks to set up a joint venture potentially worth up to $1bn to develop medical...

    6. January 11, 2016

      Investors warm to UK science parks

      The UK’s largest portfolio of privately owned science parks has been bought by a US private equity company in a deal...

    7. January 3, 2016

      GSK and AstraZeneca prescribe different treatments

      For GlaxoSmithKline and AstraZeneca — twin pillars of Britain’s pharmaceuticals sector — 2016 promises to be a critical...

    8. December 15, 2015

      Sanofi/Boehringer: swap shop

      Swapping assets was a form of human trade since long before bankers and their fees arrived on the scene. In...

    9. December 15, 2015

      Sanofi seeks to expand in consumer health with €18bn asset swap

      Sanofi has entered exclusive talks with Boehringer Ingelheim over an €18bn asset exchange that would see the French...

    10. December 15, 2015

      FDA performs U-turn over restriction of pain drug

      US regulators have taken the rare step of reversing a decision aimed at curbing the use of a pain medicine after the...

    11. December 7, 2015

      Race to control costs of cancer therapy revolution

      It is three and a half years since Emily Whitehead from Pennsylvania was given an experimental treatment for her acute...

    12. December 6, 2015

      China healthcare: Missing a beat

      Not long after taking the helm of GlaxoSmithKline in 2008, Sir Andrew Witty visited Shanghai to deliver a message along...

    13. November 26, 2015

      Unhealthy drugs: Pharma struggles with its reputation

      An industry dedicated to saving and extending lives might be expected to find empathy easy. Instead, some of the...

    14. November 17, 2015

      GSK and the perils of prudence

      Since the low point of the financial crisis almost seven years ago, stock markets have sent a clear message: do not...

    15. November 13, 2015

      Animal health: double or quits

      Sea lice. Fowl pox. Swine fever. Foot-and-mouth. Animal diseases often take prosaic names. This does not make them...

    16. November 3, 2015

      GSK unveils new drugs to boost growth

      GlaxoSmithKline has revealed details of dozens of new drugs that it says will help drive recovery in the UK...

    17. November 3, 2015

      Blood cell therapy puts Wallonia ahead in biotech race

      A technology called Car-T therapy — which involves re-engineering a patient’s disease-fighting white blood cells so...

    18. November 2, 2015

      Pfizer spurned by GSK before Allergan talks

      Pfizer approached GlaxoSmithKline about a possible takeover in recent weeks but was rebuffed before confirming its...

    19. October 27, 2015

      Novartis to pay $390m to settle kickback claims

      Novartis will pay $390m to settle US allegations that it used kickbacks to specialist pharmacies to push sales of some...

    20. October 6, 2015

      Bristol-Myers to pay SEC $14m to settle China bribery claim

      US drugmaker Bristol-Myers Squibb is to pay $14m in penalties to US authorities over alleged “improper payments” made...

    21. October 2, 2015

      Law firms implement tactics to level the playing field

      In March, GlaxoSmithKline and Novartis completed a landmark $23bn asset swap that was widely hailed as a template for...

    22. September 24, 2015

      Pharmaceuticals: Value over volume

      It was probably the most expensive tweet in history. A 21-word missive from Hillary Clinton on Monday wiped more than...

    23. September 15, 2015

      Philips to spin off lighting arm and step up medical tech drive

      From the earliest lightbulbs and transistor radios to the first flatscreen televisions, Philips was Europe’s...

    24. September 3, 2015

      Novartis launches first biological copycat drug in US

      Novartis has launched the first cut-price copy of an expensive biological drug in the US, opening the way for a new...

    25. FT Alphaville

      August 21, 2015

      Opening Quote: Beware China's bemused markets

      You can sign up for the full, pre-market email briefing here Art provocateur Banksy is opening a “bemusement park”...

    26. August 10, 2015

      Australia’s CSL warns of biotech bubble

      CSL, the Australian company that recently bought Novartis’s influenza business, has warned of a “biotech bubble” amid a...

    27. July 29, 2015

      HIV/Aids treatments stand out as GSK promises 40-drug pipeline

      GlaxoSmithKline flagged a pipeline of 40 new drugs in advanced clinical trials as it beat market forecasts for the...

    28. July 22, 2015

      Alzheimer’s breakthrough hopes add to promise of pharma revival

      Hopes of a breakthrough against Alzheimer’s disease have been boosted by encouraging clinical trial data from Eli Lilly...

    29. July 21, 2015

      Novartis chief looks to blockbuster drugs to counter profits drop

      Novartis’s chief executive has urged investors to look beyond the Swiss group’s disappointing second-quarter results...

    30. July 15, 2015

      Celgene: tomorrow’s growth today

      If all goes as planned, $7.2bn will look cheap. That is what US biotech Celgene will pay for Receptos, which will have...

    31. July 12, 2015

      Drugmakers premiere summer blockbusters

      Blockbuster drugs are back. A wave of new multibillion-dollar medicines for heart disease and high cholesterol, added...

    32. June 12, 2015

      Boardroom trades, June 13

      The future is looking bright for Oxford BioMedica , which specialises in gene and cell therapy. The company announced...

    33. June 7, 2015

      Novartis chief backs shake-up in drug pricing

      Pharmaceutical companies must move towards new pricing models based on outcomes for patients if Europe’s cash-strapped...

    34. May 6, 2015

      GSK: Hard choice

      GlaxoSmithKline chief Andrew Witty is taking the right decisions. And he had better be: his company remains in a very...

    35. May 6, 2015

      GSK drops plans for IPO of HIV drugs unit

      GlaxoSmithKline has dropped plans to sell part of its HIV drugs unit and promised to hold its dividend steady for the...

    36. April 26, 2015

      No end in sight to wave of pharma dealmaking

      Since the start of last year, pharmaceuticals companies have agreed $462bn of mergers and acquisitions — greater than...

    37. April 23, 2015

      Novartis starts to reap rewards of revamp

      Novartis announced better than expected first-quarter profits on Thursday as it began to show the benefits of a...

    38. April 17, 2015

      Mylan dismisses takeover interest from Teva Pharmaceuticals

      Israel’s Teva Pharmaceuticals is considering a bid to acquire rival generic drugmaker Mylan even as the $33bn US...

    Search for Novartis AG and